Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Clinical Pathology 2009;62:886-891; doi:10.1136/jcp.2008.063677
Copyright © 2009 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLES

Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis

E S K Ma1, C L P Wong1, F B F Law1, W-K Chan2, D Siu3

1 Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China
2 Division of Histopathology, Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China
3 Medical Oncology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China

Correspondence to:
Correspondence to Dr Edmond S K, Ma, Clinical Pathology Laboratory, 1/F Li Shu Fan Block, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong, China; eskma{at}hksh.com

Aims: Mutation of the KRAS gene predicts the clinical response to the monoclonal antibody cetuximab in patients with advanced colorectal cancer (CRC). This study aimed to perform KRAS mutation detection on formalin-fixed paraffin-embedded (FFPE) tumour tissue by two different methods for comparison.

Methods: The FFPE sample was microdissected to enrich for tumour cells. KRAS exon 2 mutations were performed on 100 Chinese patients with CRC by direct nucleotide sequencing and high-resolution melting (HRM) analysis.

Results: KRAS exon 2 mutations were detected in a total of 62 patients with the two methods combined, comprising 11 different mutant alleles. Three common mutations p.Gly12Asp, p.Gly12Val and p.Gly13Asp accounted for approximately 70% of all cases. The concordant rate between the two methods was 95%. Four mutations not initially detected by direct sequencing were identified by HRM and confirmed by sequencing of the HRM amplicons. One mutation detected by direct sequencing was inadvertently grouped as a wild-type allele by HRM software, but this was readily rectified through manual review.

Conclusion: HRM analysis is a sensitive method of detecting KRAS mutation on FFPE tumour tissue to guide cetuximab treatment and is applicable to routine molecular diagnostic service. Utilisation of HRM to screen for mutations upfront economises the resource used in the sequencing reaction.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs